Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The first approved combination therapy against cystic fibrosis will open up an increasing proportion of patients for treatment. As Anna Azvolinsky reports, companies are banking on it.
The recent publication of a simple procedure for creating a CRISPR-Cas9-mediated gene drive has some researchers sounding the alarm. What are the risks to populations in the wild and what precautions are necessary? Laura DeFrancesco investigates.
Personal health data are beginning to be shared in the digital world—on mobile devices and the internet. Is the loss of privacy a price worth paying for the presumed benefits? Laura DeFrancesco investigates.
Companies exploring biotech approaches to flavor and fragrance production must navigate challenges in regulations, market dynamics and public perception. Emily Waltz investigates.
Using conventional drug discovery and novel synthetic biology approaches, some investigators and companies are mining our resident microbes and their metabolites for targets in small-molecule drug programs. Ken Garber reports.
Approvals of new chemical and biologic entities surged again in 2014, shepherded along by a confident FDA, as industry reaped the rewards of drug development incentives. Chris Morrison reports.
The drug industry is struggling to find ways of engaging with consumers on social media. Failure to adapt may bring substantial opportunity costs, argues Virginia Hughes.
